Want to see SG:9G2 full AI Analyst Report?
9G2 Stock Chart & Stats
S$0.03
>-S$0.01(-3.45%)
At close: 4:00 PM EDT
S$0.03
>-S$0.01(-3.45%)
Day’s Range― - ―
52-Week RangeS$0.03 - S$0.08
Previous CloseN/A
Volume50.00K
Average Volume (3M)1.22M
Market Cap
S$46.55M
Enterprise ValueS$106.62
Total Cash (Recent Filing)S$15.18M
Total Debt (Recent Filing)S$61.28M
Price to Earnings (P/E)―
Beta-0.35
Next Earnings
Feb 12, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,724,092,500
10 Day Avg. Volume1,248,150
30 Day Avg. Volume1,216,190
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.70
Price to Sales (P/S)2.35
P/FCF Ratio-8.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginA gross margin of about 92% indicates the underlying medical service offering has attractive direct economics. If revenue stabilizes, this margin profile could provide meaningful operating leverage, although the company must still address overhead and other costs that currently absorb the gross profit.
Lower LeverageThe substantial improvement in leverage from 2022–2023 gives the company a stronger balance-sheet position than in earlier periods. Positive equity and reduced debt relative to equity can improve financial flexibility, even though the current capital structure remains meaningful and losses limit self-funding.
Narrower Cash BurnThe reduction in operating cash burn during 2026 is an encouraging sign that cash losses may be moving in the right direction. Sustaining this improvement would reduce external funding needs over the next several quarters, though free cash flow remains negative and the business has not yet reached cash-generation breakeven.
Bears Say
Severe UnprofitabilityPersistent, very large losses relative to revenue indicate that high gross margins are being overwhelmed by overhead and other costs. This weak profitability limits retained capital, reduces the ability to fund expansion internally, and leaves the business vulnerable if revenue does not recover.
Revenue ContractionA material revenue decline weakens operating leverage and makes it harder to absorb the company’s cost base. Because profitability is already deeply negative, continued contraction could prolong losses, delay the path to breakeven, and increase reliance on funding or restructuring actions.
Persistent Cash ConsumptionRepeatedly negative operating and free cash flow shows that the business consumes cash rather than independently financing its operations. Even with some improvement in operating burn, ongoing outflows raise funding risk and can constrain investment, debt reduction, and other strategic choices.
Singapore Institute of Advanced Medicine Holdings Ltd. News
9G2 FAQ
What was Singapore Institute of Advanced Medicine Holdings Ltd.’s price range in the past 12 months?
Singapore Institute of Advanced Medicine Holdings Ltd. lowest share price was S$0.03 and its highest was S$0.08 in the past 12 months.
What is Singapore Institute of Advanced Medicine Holdings Ltd.’s market cap?
Singapore Institute of Advanced Medicine Holdings Ltd.’s market cap is S$46.55M.
When is Singapore Institute of Advanced Medicine Holdings Ltd.’s upcoming earnings report date?
Singapore Institute of Advanced Medicine Holdings Ltd.’s upcoming earnings report date is Feb 12, 2027 which is in 146 days.
How were Singapore Institute of Advanced Medicine Holdings Ltd.’s earnings last quarter?
Singapore Institute of Advanced Medicine Holdings Ltd. released its earnings results on May 14, 2026. The company reported -S$0.004 earnings per share for the quarter.
Is Singapore Institute of Advanced Medicine Holdings Ltd. overvalued?
According to Wall Street analysts Singapore Institute of Advanced Medicine Holdings Ltd.’s price is currently Overvalued.
Does Singapore Institute of Advanced Medicine Holdings Ltd. pay dividends?
Singapore Institute of Advanced Medicine Holdings Ltd. does not currently pay dividends.
What is Singapore Institute of Advanced Medicine Holdings Ltd.’s EPS estimate?
Singapore Institute of Advanced Medicine Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Singapore Institute of Advanced Medicine Holdings Ltd. have?
Singapore Institute of Advanced Medicine Holdings Ltd. has 1,724,092,500 shares outstanding.
What happened to Singapore Institute of Advanced Medicine Holdings Ltd.’s price movement after its last earnings report?
Singapore Institute of Advanced Medicine Holdings Ltd. reported an EPS of -S$0.004 in its last earnings report. Following the earnings report the stock price went down -6.522%.
Which hedge fund is a major shareholder of Singapore Institute of Advanced Medicine Holdings Ltd.?
Currently, no hedge funds are holding shares in SG:9G2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Singapore Institute of Advanced Medicine Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.63%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Singapore Institute of Advanced Medicine Holdings Ltd.
Singapore Institute of Advanced Medicine Holdings Ltd. operates as a holding company primarily focused on delivering healthcare services. Its operations include providing pharmaceutical products, surgical supplies, and medical laboratory services. The company was founded by Djeng Shih Kien on November 24, 2011, and is headquartered in Singapore.
Singapore Institute of Advanced Medicine Holdings Ltd. (9G2) Earnings & Revenues
Technical Analysis
Raffles Medical Group
―
Thomson Medical Group Ltd.
―
HC Surgical Specialists Ltd
―
ISEC Healthcare Ltd
―
OUE Lippo Healthcare Limited
―